MODIFICATION TO: ACCUSIGN RC DOA 10 (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP

K062575 · Princeton BioMeditech Corp. · LAG · Nov 26, 2007 · Clinical Toxicology

Device Facts

• Record ID: K062575
• Device Name: MODIFICATION TO: ACCUSIGN RC DOA 10 (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP
• Applicant: Princeton BioMeditech Corp.
• Product Code: LAG · Clinical Toxicology
• Decision Date: Nov 26, 2007
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3610
• Device Class: Class 2

Indications for Use

Immunoassay for the qualitative detection of methamphetamine, opiates, cocaine metabolite, THC metabolite, phencyclidine, benzodiazepines, barbiturates, tricyclic antidepressants, methadone, and amphetamine in human urine to assist in screening of drug of abuse samples. The detecting cut-off concentrations are as follows: MET D-Methamphetamine 1000 ng/mL OPI Morphine 300 ng/mL COC Benzoylecgonine 300 ng/mL THC 11-nor-Δ⁹-9-carboxylic acid 50 ng/mL PCP Phencyclidine 25 ng/mL Benzodiazepine Oxazepam 300 ng/mL Barbiturate Secobarbital 300 ng/mL Methadone Methadone 300 ng/mL TCA Nortriptyline 1000 ng/mL AMP D-Amphetamine 1000 ng/mL This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS)/ High performance liquid chromatography (HPLC, for TCA) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.

Device Story

Lateral flow immunochromatographic assay; detects 10 drugs of abuse in human urine. Sample (3 drops) added to test well; migrates via capillary action. Competitive binding mechanism: drug in sample competes with dye-labeled drug conjugate for limited immobilized antibodies on membrane. Absence of line in test window indicates positive result (drug saturation); presence of line indicates negative result. Control line confirms proper migration. Used in clinical settings; read visually or via DXpress Reader. Provides preliminary results; requires GC/MS or HPLC confirmation. Assists clinicians in drug screening decisions.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on identical formulation, reagents, and manufacturing processes to the predicate device.

Technological Characteristics

Solid-phase chromatographic membrane immunoassay. Lateral flow format. Qualitative detection via competitive binding. Analyte-specific antibodies immobilized on membrane. DXpress Reader or visual interpretation. No specific materials or standards cited. Sterilization not specified.

Indications for Use

Indicated for qualitative screening of 10 drugs of abuse (methamphetamine, opiates, cocaine, THC, phencyclidine, benzodiazepines, barbiturates, tricyclic antidepressants, methadone, amphetamine) in human urine. For prescription use only.

Regulatory Classification

Identification

A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose.

Special Controls

*Classification.* Class II (special controls). A methamphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• AccuSign® DOA10 (k983501)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k062575

B. Purpose for Submission:
New device

C. Measurand:
Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Methamphetamine, Phencyclidine, Methadone, Opiates, THC, and Tricyclic Antidepressants.

D. Type of Test:
Qualitative immunoassay

E. Applicant:
Princeton BioMeditech Corporation

F. Proprietary and Established Names:
AccuSign RC DOA10 (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)
StatusFirst DOA10 (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)

G. Regulatory Information:

| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| LAG | II | 862.3610
Methamphetamine test system | 91 (Tox) |
| DJG | II | 862.3650, Enzyme Immunoassay, Opiates | 91 (Tox) |
| DIO | II | 862.3250, Enzyme Immunoassay, Cocaine and Cocaine Metabolites | 91 (Tox) |

{1}

| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DKE | II | 862.3870
Cannabinoid test system | 91 (Tox) |
| LCM | Unclassified (510k required) | 862.3100 Enzyme immunoassay, Phencyclidine | 91 (Tox) |
| DKZ | II | 862.3100 Amphetamine test system | 91 (Tox) |
| JXM | II | 862.3170 Enzyme immunoassay, Barbiturate | 91 (Tox) |
| DIS | II | 862.3150 Barbiturate test system | 91 (Tox) |
| DJR | II | 862.3620 Methadone test system | 91 (Tox) |
| LFI | II | 862.3910 Tricyclic antidepressant drugs test system | 91 (Tox) |

H. Intended Use:

1. Intended use(s):
See indications for use below.

2. Indication(s) for use:
Immunoassay for the qualitative detection of methamphetamine, opiates, cocaine metabolite, THC metabolite, phencyclidine, benzodiazepines, barbiturates, tricyclic antidepressants, methadone, and amphetamine in human urine to assist in screening of drug of abuse samples. The detecting cut-off concentrations are as follows:

MET D-Methamphetamine 1000 ng/mL
OPI Morphine 300 ng/mL
COC Benzoylecgonine 300 ng/mL
THC 11-nor-Δ⁹-9-carboxylic acid 50 ng/mL
PCP Phencyclidine 25 ng/mL
Benzodiazepine Oxazepam 300 ng/mL
Barbiturate Secobarbital 300 ng/mL
Methadone Methadone 300 ng/mL
TCA Nortriptyline 1000 ng/mL
AMP D-Amphetamine 1000 ng/mL

{2}

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS)/ High performance liquid chromatography (HPLC, for TCA) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.

3. Special conditions for use statement(s):

For prescription use only.

Certain foods or medications containing opiates or opiate derivatives, amphetamines, methamphetamine, barbiturate, benzodiazepines, or tricyclics may produce a positive result in any chemical or immunological assay. Poppy seeds can contain opiates or ingestion of products containing poppy seeds can cause a positive result.

4. Special instrument requirements:

For use with the DXpress Reader or as a visually read test.

I. Device Description:

The AccuSign RC DOA 10 and the Status First DOA 10 are one-step immunoassays that are sold in two packaging: 10 tests or 35 test kits. Each individual test contains the test device, disposable sample dispenser and instructions for use booklet.

J. Substantial Equivalence Information:

1. Predicate device name(s):

AccuSign DOA 10, hCG Pregnancy Test and NT proBNP Test

2. Predicate K number(s):

k983501, k050955 and k051596

3. Comparison with predicate:

The following chart compares the device with the AccuSign DOA 10 (k983501)

| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended use | For the qualitative detection of 10 drugs of abuse in human urine | Same |
| Assay principle | Lateral flow immunochromatographic | Same |

{3}

| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| | assay | |
| Test Procedure | Add 3 drops of urine into the sample well | Same |
| Result reading time | 5 min | Same |
| Matrix | Human urine | Same |
| Volume | 3 drops | Same |
| Detection Cutoff | MET 1000 ng/mL
OPI 300 ng/mL
COC 300 ng/mL
THC 50 ng/mL
PCP 25 ng/mL
Benzod. 300 ng/mL
Barbiturate 300 ng/mL
Methadone 300 ng/mL
TCA 1000 ng/mL
AMP 1000 ng/mL | Same |
| **Differences** | | |
| Reading Method | DXpress Reader or visual | Visual only |

K. Standard/Guidance Document Referenced (if applicable):
None referenced.

L. Test Principle:
The AccuSign RC•DOA10 test uses solid-phase chromatographic membrane immunoassay technology for the qualitative, simultaneous detection of methamphetamine, opiates, cocaine, THC, phencyclidine, benzodiazepines, barbiturates, methadone, tricyclic antidepressants, and amphetamine in human urine. The test relies on competitive binding of the antibodies between drug conjugate and drug which may be present in the urine sample. A sample of urine is placed in the sample well of the device and is allowed to migrate upward. If the drug is present in the urine sample, it competes with the drug conjugate, which is bound to the dye, for the limited antibodies immobilized on the membrane. If the drug or drug metabolite levels are above the cutoff level, the drug will saturate the antibodies, thus inhibiting the binding of the dye coated with drug conjugates to the antibodies on the membrane. This prevents the formation of a line on the membrane. Therefore, a preliminary drug-positive urine sample will not generate a line in the test window, indicating a positive result from positive drug competition, while a negative urine sample will generate a line in the test window, indicating a negative result from an absence of competition with free drugs.

In addition to the Test line that may appear in the Test window (T), a Control line is present in the Control window (C) which should always appear if sufficient sample volume is used applied and the sample migrates correctly up the test strip membrane.

{4}

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The sponsor conducted precision studies for each drug on the DOA 10 panel. Spiked urine controls with concentrations of 0, 50% below cutoff, 25% below cutoff, cutoff, +25% above cutoff, 50% above cutoff and 100% above cutoff levels were tested. Ten devices at each concentration were tested on three readers for two days with two lots of test devices by three operators (total 40 tests per level, per operator). The samples were aliquoted and randomly given to operators for a blind study. The test result was visually read at 5 minutes after adding urine sample and then immediately read with the DXpress reader. There were no significant differences between readers, operators, between days or between lots for the ten tests on the panel.

| Drug name cutoff (ng/mL) | Conc. (ng/ml) | Total (Reader) | | Total (Visual) | |
| --- | --- | --- | --- | --- | --- |
| | | pos./neg. | % agree-ment | pos./neg. | % agree-ment |
| MET 1000 | 0 | 0/120 | 100 | 0/120 | 100 |
| | 500 | 0/120 | 100 | 0/120 | 100 |
| | 750 | 22/98 | 82 | 17/103 | 86 |
| | 1000 | 73/47 | N/A | 64/56 | N/A |
| | 1250 | 113/7 | 94 | 113/7 | 94 |
| | 1500 | 119/1 | 99 | 120/0 | 100 |
| | 2000 | 120/0 | 100 | 120/0 | 100 |
| OPI 300 | 0 | 0/120 | 100 | 0/120 | 100 |
| | 150 | 0/120 | 100 | 0/120 | 100 |
| | 225 | 1/119 | 99 | 3/117 | 98 |
| | 300 | 58/62 | N/A | 60/60 | N/A |
| | 375 | 99/21 | 83 | 101/19 | 84 |
| | 450 | 117/3 | 98 | 117/3 | 98 |
| | 600 | 120/0 | 100 | 120/0 | 100 |
| COC 300 | 0 | 0/120 | 100 | 0/120 | 100 |
| | 150 | 1/119 | 99 | 1/119 | 99 |
| | 225 | 30/90 | 75 | 28/92 | 77 |
| | 300 | 83/37 | N/A | 74/46 | N/A |
| | 375 | 111/9 | 93 | 109/11 | 91 |
| | 450 | 120/0 | 100 | 120/0 | 100 |
| | 600 | 120/0 | 100 | 120/0 | 100 |
| THC | 0 | 0/120 | 100 | 0/120 | 100 |
| | 25 | 0/120 | 100 | 0/120 | 100 |
| | 37.5 | 9/111 | 93 | 9/111 | 93 |
| | 50 | 72/48 | N/A | 59/61 | N/A |

{5}

| Drug name cutoff (ng/mL) | Conc. (ng/ml) | Total (Reader) | | Total (Visual) | |
| --- | --- | --- | --- | --- | --- |
| | | pos./ neg. | % agree- ment | pos./ neg. | % agree- ment |
| 50 | 62.5 | 109/11 | 91 | 107/13 | 89 |
| | 75 | 117/3 | 98 | 118/2 | 98 |
| | 100 | 120/0 | 100 | 120/0 | 100 |
| PCP | 0 | 0/120 | 100 | 0/120 | 100 |
| | 12.5 | 0/120 | 100 | 0/120 | 100 |
| | 18.75 | 6/114 | 95 | 4/116 | 97 |
| 25 | 25 | 68/52 | N/A | 70/50 | N/A |
| | 31.25 | 117/3 | 98 | 115/5 | 96 |
| | 37.5 | 119/1 | 99 | 119/1 | 99 |
| | 50 | 120/0 | 100 | 120/0 | 100 |
| BZO | 0 | 0/120 | 100 | 0/120 | 100 |
| | 150 | 0/120 | 100 | 0/120 | 100 |
| | 225 | 24/96 | 80 | 23/97 | 81 |
| 300 | 300 | 77/43 | N/A | 71/49 | N/A |
| | 375 | 110/10 | 92 | 109/11 | 92 |
| | 450 | 120/0 | 100 | 118/2 | 98 |
| | 600 | 120/0 | 100 | 120/0 | 100 |
| BAR | 0 | 0/120 | 100 | 0/120 | 100 |
| | 150 | 3/117 | 98 | 0/120 | 100 |
| | 225 | 27/93 | 78 | 27/93 | 78 |
| 300 | 300 | 81/39 | N/A | 69/51 | N/A |
| | 375 | 110/10 | 92 | 110/10 | 92 |
| | 450 | 120/0 | 100 | 120/0 | 100 |
| | 600 | 120/0 | 100 | 120/0 | 100 |
| MTD | 0 | 0/120 | 100 | 0/120 | 100 |
| | 150 | 2/118 | 98 | 2/118 | 98 |
| | 225 | 32/88 | 73 | 36/84 | 70 |
| 300 | 300 | 90/30 | N/A | 78/42 | N/A |
| | 375 | 112/8 | 93 | 109/11 | 91 |
| | 450 | 119/1 | 99 | 119/1 | 99 |
| | 600 | 120/0 | 100 | 120/0 | 100 |
| TCA | 0 | 0/120 | 100 | 0/120 | 100 |
| | 500 | 0/120 | 100 | 0/120 | 100 |
| | 750 | 5/115 | 96 | 8/112 | 93 |
| 1000 | 1000 | 63/57 | N/A | 69/51 | N/A |
| | 1250 | 101/19 | 84 | 99/21 | 83 |
| | 1500 | 119/1 | 99 | 120/0 | 100 |
| | 2000 | 120/0 | 100 | 120/0 | 100 |
| AMP | 0 | 0/120 | 100 | 0/120 | 100 |
| | 500 | 1/119 | 99 | 1/119 | 99 |
| | 750 | 27/93 | 78 | 32/88 | 73 |
| | 1000 | 92/28 | N/A | 80/40 | N/A |

{6}

| Drug name cutoff (ng/mL) | Conc. (ng/ml) | Total (Reader) | | Total (Visual) | |
| --- | --- | --- | --- | --- | --- |
| | | pos./ neg. | % agree-ment | pos./ neg. | % agree-ment |
| 1000 | 1250 | 116/4 | 97 | 115/5 | 96 |
| | 1500 | 118/2 | 98 | 118/2 | 98 |
| | 2000 | 120/0 | 100 | 120/0 | 100 |

b. Linearity/assay reportable range:

Not applicable for a qualitative assay.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

This device has internal process controls. A colored line appearing in the control region confirms that sufficient sample volume was added and that the sample migrated correctly up the test strip membrane.. Users are informed not to interpret the test if a colored line failed to appear in the control region.

External controls are not supplied with this device. The sponsor recommends the use of commercially available controls to be used with the DXpress Reader. The DXpress reader will report "Control:Valid" and test result only if the internal process controls are satisfied.

Stability testing of the test strips was previously reviewed under k983501. To validate this claim using both the reader and strips visually read, the sponsor performed additional stability studies. The results from these studies showed expected results for all concentrations and support the sponsor real time 15 month stability claim.

d. Detection limit:

A cutoff value validation study (see precision section above for a summary of the data) was conducted at seven different drug concentrations to include 0, +/- 50% of the cutoff, +/- 75% of the cutoff, the cutoff and +100% of the cutoff. The samples used were GC/MS or HPLC confirmed. Three operators were used to analyze two assay lots. The results demonstrate performance at the sponsor's chosen cutoffs of methamphetamine as 1000 ng/mL, opiates as 300 ng/mL, cocaine as 300 ng/mL, THC as 50 ng/mL, PCP as 25 ng/mL, benzodiazepine as 300 ng/mL, barbiturate as 300 ng/mL, methadone as 300 ng/mL, TCA as 1000 ng/mL, amphetamine as 1000 ng/mL.

e. Analytical specificity:

e.1. Cross reactivity

The following table lists compounds that are detected by the AccuSign® RC-DOA10 (MET/OPI/ COC/THC/PCP//BAR/BEZ/MTD/TCA/AMP) test. The specificity of the AccuSign® RC-DOA 10 test was determined by adding

{7}

various drugs and drug metabolites to the pooled drug-negative urine specimens and testing with the AccuSign® RC·DOA10 test. The cross reactivity in the following tables were tested with both the reader and the visual tests. The results are expressed in terms of the minimum concentration required to produce a positive result.

| MET | Cross ReactingConcentration (ng/mL) |
| --- | --- |
| D-Amphetamine | >100,000 |
| D,L-Amphetamine | >100,000 |
| (-)Ephedrine | >100,000 |
| (+)Ephedrine | >100,000 |
| Isometheptene | 12,500 |
| D-Methamphetamine | 1,000 |
| p-OH-Methamphetamine | 3,000 |
| Methylenedioxyamphetamine | >100,000 |
| Methylenedioxymethamphetamine | 1,000 |
| Methylenedioxyethylamphetamine(MDEA) | >100,000 |
| OPI | |
| --- | --- |
| Codeine | 300 |
| Hydrocodone | 500 |
| Hydromorphone | 500 |
| Lavofloxacin | 100,000 |
| Levophanol | 5000 |
| Meperidine | >100,000 |
| Morphine | 300 |
| Morphine-3-β-D-glucuronide | 300 |
| Nalorphine | 15,000 |
| Naloxone | >100,000 |
| Norcodeine | >100,000 |
| Oxycodone | 5,000 |
| Oxymorphone | 20,000 |
| Thebaine | 10,000 |
| Tramadol | >100,000 |
| COC | |
| --- | --- |
| Benzoylecgonine | 300 |
| Cocaine HCl | >100,000 |
| Ecgonine HCl | >100,000 |
| THC | |
| --- | --- |
| Cannabinol | 10,000 |
| 11-nor-Δ⁸-THC-9-COOH | 100 |
| 11-nor-Δ⁹-THC-9-COOH | 50 |
| Δ⁸-THC | 10,000 |

{8}

9

$\Delta^{9}$-THC 5,000
11-hydroxy-$\Delta^{9}$-THC 4,000

PCP
Phencyclidine 25
Thienylcyclohexyl-piperidine 450

BZO
Alprazolam 100,000
Bromazepam 1,250
Chlordiazepoxide 500
Clobazam >100,000
Clonazepam 30,000
Clorazepate dipotassium 2000
Delorazepam 1,500
N-Desalkylflurazepam 2,500
Diazepam 10,000
Estazolam >100,000
Flunitrazepam >100,000
7-amino flunitrazepam 1,500
a-Hydroxyalprazolam 100,000
a-Hydroxytriazolam 10,000
Lorazepam 2,500
Lormetazepam 25,000
Medazepam 10,000
Midazolam 25,000
Nitrazepam 100,000
Nordiazepam(N-Desmethyldiazepam) 7,500
Oxazepam 300
Prazepam >100,000
Temazepam 6,000
Triazolam >100,000

BAR
Allobarbital 400
Alphenal 250
Amobarbital 5,000
Aprobarbital 400
Barbital 1,500
Butalbital 800
Cyclopentobarbital 400
Pentobarbital 2,000
Phenobarbital 5,000
Penytoin 4,000

{9}

10

Secobarbital 300
Thiopental >100,000

MTD
Diphenhydramine >100,000
Doxylamine >100,000
EDDP >100,000
EMDP >100,000
Imipramine >100,000
LAAM 900
Methadone 300
Meperidine >100,000
Nor-LAAM 3,000

TCA
Amitryptiline 800
Chlorpromazine 100,000
Clomipramine 5,000
Cyclobenzaprine 2,500
Desipramine 1,500
Diphenhydramine >100,000
Dothiepin 2,000
Doxepin 1,500
Imipramine 1,000
Norclomipramine 850
Nordoxepin 5,000
Nortriptyline 1,000
Perphenazine 41,000
Promazine 5,000
Protryptiline 2,000
Trimipramine 3,000

AMP
D-Amphetamine 1,000
D,L-Amphetamine 1,800
L-Amphetamine 37,500
Benzphetamine >100,000
d-Methamphetamine >100,000
p-OH-Methamphetamine >100,000
Methylenedioxyamphetamine 2,000
Methlyenedioxymethamphetamine >100,000
β-Phenylethylamine 40,000
l-Phenylpropanolamine >100,000

{10}

Phentermine $>100,000$

Tryptamine 50,000

Tyramine 70,000

3-OH-Tyramine 50,000

# e.2. Interference

Each compound was added with the concentration given below to urine samples which had $50\%$ or $150\%$ cutoff concentration of each drug. Each spiked urine sample was tested in triplicate. The result was interpreted as no interference if $50\%$ cutoff level urine sample with spiked compound showed negative result and $150\%$ cutoff level urine sample with spiked compound showed positive result. No interference was observed at the concentration below.

| Compounds | Test Concentration (mg/dL) |
| --- | --- |
| Protein | 2000 |
| Hemoglobin | 25 |
| Bilirubin | 2 |
| Glucose | 1500 |
| Creatinine | 20 |
| Sodium Nitrite | 100 |
| Sodium Chloride | 1500 |

Additionally, the sponsor tested many common substances and biological materials (104) for cross-reactivity with the drug of abuse tests at a concentration of $100\mu \mathrm{g / mL}$ in drug-free and drug positive urines. The sponsor states that they was no cross-reactivity detected with the visual tests. The compounds are listed in the package insert.

# e.3 Urinary pH

The effect of urine sample pH on the assay result was examined. The pH 4.5 to pH 8.5 urine samples were tested with concentrations of $50\%$ cutoff level and $150\%$ cutoff level for each drug. At each pH and each concentration the test was repeated 10 times. There was no discrepancy from expected in the results with different pHs and showed that there was no interference from urine pH ranging from 3 to 9.

# e.4. Specific gravity

The effect of specific gravity of urine samples on the test result was examined. The urine samples with specific gravity 1.002 and 1.04 were tested at $50\%$ cutoff level and $150\%$ cutoff levels for each drug. At each specific gravity and each concentration the test was repeated ten times. There was no discrepancy from expected in the results with different

{11}

specific gravity and showed that there was no interference from specific gravity.

# f. Assay cut-off:

Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision above.

# 2. Comparison studies:

# a. Method comparison with predicate device:

The performance of AccuSign® RC·DOA10 was evaluated in comparison to the result of GC/MS (HPLC for TCA). Over 40 clinical samples which contain drugs were tested and the results were compared to the GC/MS or HPLC values. Additionally, the sponsor tested 100 drug negative samples were collected from people who apparently were not taking the drug. All test results were read visually and with the DXpress reader. There was no significant difference between the reader and the visual test results. The table below lists the compounds analyzed by GC/MS or HPLC and the results of the method comparison study.

Compounds that were found in the clinical samples tested

| Drug | Compounds analyzed for each drug |
| --- | --- |
| THC | 11-nor-Δ-9-carboxy-THC |
| OPI | Morphine, Codeine, Oxycodone, Oxymorphone, 6-Acetylmorphine |
| COC | Benzoylecgonine |
| MET | Methamphetamine, Amphetamine |
| AMP | Amphetamine, Methamphetamine |
| PCP | Phencyclidine |
| BZO | Oxazepam, Nordiazepam, Temazepam, 7-aminoclonazepam, Lorazepam, Alprazolam, a-Hydroxyalprazolam |
| BAR | Secobarbital, Butalbital, Phenobarbital, Amobarbital |
| MTD | Methadone, EDDP |
| TCA | Nortriptyline, Amitriptyline, Imipramine, Despramine, Doxepine, Nordoxepine, Cyclobenzaprine, Norcyclobenzaprine, Clomipramine, Norclomipramine |

{12}

| Drug Name | Negative* | | Negative (< 50% cutoff) | | Negative (50% cutoff to cutoff) | | Positive (cutoff to 150% cutoff) | | Positive (> 150% cutoff) | | % Agreement with GC/MS | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | R | V | R | V | R | V | R | V | R | V | R | V |
| THC | Pos. | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 10 | 40 | 40 | 98 (51/52)** | 96 (50/52) |
| | Neg. | 100 | 100 | 7 | 7 | 10 | 10 | 0 | 1 | 1 | 1 | 100 (117/117) | 100 (117/117) |
| OPI | Pos. | 0 | 0 | 1 | 1 | 4 | 4 | 8 | 8 | 49 | 49 | 100 (57/57) | 100 (57/57) |
| | Neg. | 100 | 100 | 15 | 15 | 8 | 8 | 0 | 0 | 0 | 0 | 96 (123/128) | 96 (123/128) |
| COC | Pos. | 0 | 0 | 0 | 0 | 2 | 2 | 5 | 5 | 47 | 47 | 98 (52/53) | 98 (52/53) |
| | Neg. | 100 | 100 | 13 | 13 | 11 | 11 | 1 | 1 | 0 | 0 | 98 (124/126) | 98 (124/126) |
| MET | Pos. | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 42 | 42 | 98 (48/49) | 98 (48/49) |
| | Neg. | 100 | 100 | 14 | 14 | 5 | 5 | 1 | 1 | 0 | 0 | 95 (119/125) | 95 (119/125) |
| PCP | Pos. | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 13 | 49 | 49 | 95 (63/66) | 94 (62/66) |
| | Neg. | 100 | 100 | 6 | 6 | 9 | 9 | 1 | 2 | 2 | 2 | 100 (115/115) | 100 (115/115) |
| BZO | Pos. | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 6 | 53 | 53 | 100 (59/59) | 100 (59/59) |
| | Neg. | 100 | 100 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 | 97 (114/117) | 97 (114/117) |
| BAR | Pos. | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 42 | 42 | 98 (46/47) | 98 (46/47) |
| | Neg. | 100 | 100 | 10 | 10 | 8 | 8 | 1 | 1 | 0 | 0 | 100 (118/118) | 100 (118/118) |
| MTD | Pos. | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 6 | 71 | 72 | 99 (77/78) | 100 (78/78) |
| | Neg. | 100 | 100 | 10 | 10 | 8 | 8 | 0 | 0 | 1 | 0 | 99 (118/119) | 99 (118/119) |
| TCA ** | Pos. | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 36 | 36 | 100 (41/41) | 100 (41/41) |
| | Neg. | 100 | 100 | 11 | 11 | 9 | 9 | 0 | 0 | 0 | 0 | 100 (120/120) | 100 (120/120) |
| AMP | Pos. | 0 | 0 | 0 | 0 | 1 | 1 | 8 | 8 | 39 | 39 | 96 (47/49) | 96 (47/49) |
| | Neg. | 100 | 100 | 16 | 16 | 13 | 13 | 2 | 2 | 0 | 0 | 99 (129/130) | 99 (129/130) |

{13}

*Negative urine samples were collected from people who apparently were not taking the drug.
**The numbers in parentheses are Correct results / Total numbers tested.

R=Reader

V=Visual

The concentration for the false positive opiate (morphine) result was 124 ng/mL. The concentrations for the false negative PCP results were 46 and 52 ng/mL. The concentration for the false negative methadone result was 822 ng/mL.

b. Matrix comparison:

Not applicable. This is a urine only assay

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable.

b. Clinical specificity:

Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

4. Clinical cut-off:

Not applicable.

5. Expected values/Reference range:

Not applicable.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.